Robert W. Baird Initiates Coverage on GTx, Inc. (GTXI)
Equities researchers at Robert W. Baird started coverage on shares of GTx, Inc. (NASDAQ:GTXI) in a report issued on Tuesday. The brokerage set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s target price would indicate a potential upside of 42.26% from the company’s current price.
Separately, Stifel Nicolaus assumed coverage on GTx in a research note on Thursday, November 9th. They set a “buy” rating for the company.
GTx (NASDAQ GTXI) opened at $11.95 on Tuesday. GTx has a one year low of $2.73 and a one year high of $12.96.
GTx (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). analysts anticipate that GTx will post -1.48 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/23/robert-w-baird-initiates-coverage-on-gtx-inc-gtxi.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Caxton Corp acquired a new position in GTx during the 3rd quarter worth $531,000. Abingworth LLP acquired a new position in GTx during the 3rd quarter worth $2,781,000. Finally, Bank of New York Mellon Corp acquired a new position in GTx during the 2nd quarter worth $124,000. 9.02% of the stock is owned by hedge funds and other institutional investors.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.